How did the Otezla acquisition impact Amgen's financial results in Q1 2020?

The acquisition of Otezla, completed in November 2019, significantly contributed to Amgen's revenue growth. In its first full quarter of reporting (Q1 2020), Otezla generated $479 million in product sales, driving the overall increase in total revenues. However, it also led to higher operating expenses, including cost of sales and selling, general, and administrative expenses, as well as amortization of intangible assets, which impacted net income and EPS.

What is the impact of COVID-19 on Amgen's business as reported in this filing?

Amgen noted that the COVID-19 pandemic is impacting its business in several ways. This includes changes in demand for certain products (e.g., lower demand for Prolia due to patients avoiding doctor's offices), temporary pauses in enrollment for some clinical trials, and a shift to remote work for employees. The company has implemented measures to ensure business continuity and employee safety and does not currently expect significant disruptions to its medicine supply. However, there is uncertainty regarding the pandemic's full impact on future sales, clinical development timelines, and the broader economic environment.

How did Amgen's debt and equity management perform in Q1 2020?

Amgen actively managed its capital structure during the quarter. The company issued $5.0 billion in new debt while also repaying $3.3 billion of existing debt. It returned significant capital to shareholders through $933 million in stock repurchases and $945 million in dividends. Despite these capital return activities and the accumulated deficit, the company's financial position remains strong, with existing funds and cash flow expected to meet its obligations.

Are there any major legal or tax issues Amgen is currently facing?

Amgen is involved in ongoing patent litigations related to several of its key products, including KYPROLIS®, Otezla®, Sensipar®, ENBREL®, Repatha®, NEUPOGEN®/Neulasta®, EPOGEN®, KANJINTI®, and MVASI®. The company is also actively contesting proposed tax adjustments from the IRS for the years 2010-2015, which primarily relate to profit allocation between U.S. and Puerto Rico entities. Final resolution of these tax matters is not expected within 12 months and could materially impact financial statements.

AMGN 10-Q Quarterly Report Q1 FY2020 — Revenue, Net Income, EPS

Summary

Amgen Inc. (AMGN) reported its first quarter 2020 results, showcasing a significant increase in total revenues driven by the acquisition of Otezla and growth in key products. Total revenues rose 11% year-over-year to $6.16 billion, primarily due to a 12% increase in product sales to $5.89 billion. This growth was bolstered by strong performances from Prolia®, Repatha®, and the newly acquired Otezla®, which generated $479 million in its first full quarter. However, net income saw a slight decrease of 8% to $1.83 billion, and diluted Earnings Per Share (EPS) declined by 3% to $3.07, largely impacted by increased operating expenses, particularly related to the Otezla acquisition and amortization of intangible assets. The company also highlighted its proactive capital allocation strategy, including significant share repurchases and dividend payments, while managing its debt profile. Amgen’s cash position remains robust, supporting ongoing operations and strategic investments. The company acknowledged the emerging impact of the COVID-19 pandemic, noting potential demand shifts for certain products and temporary pauses in clinical trial enrollments, while emphasizing its commitment to employee safety and business continuity. Despite the challenges posed by the pandemic, Amgen remains focused on its pipeline and strategic initiatives.

Financial Highlights

53 data points

Beta

Revenue

$6.16B

0.7% Gross Margin

Net Income

$1.82B

0.3% Net Margin

EPS (Diluted)

$3.07

Total Assets

$61.67B

Cash & Equivalents

$7.69B

Free Cash Flow

$1.99B

Financial Statements

Beta

Revenue	$6.16B
Cost of Revenue	$1.51B
Gross Profit	$4.38B
SG&A Expenses	$1.32B
Operating Expenses	$3.81B
Operating Income	$2.35B
Interest Expense	$346.00M
Net Income	$1.82B
EPS (Basic)	$3.09
EPS (Diluted)	$3.07
Shares Outstanding (Basic)	590.00M
Shares Outstanding (Diluted)	594.00M

Key Highlights

1Total revenues increased by 11% to $6.16 billion, driven by a 12% rise in product sales to $5.89 billion.
2The acquisition of Otezla contributed significantly, generating $479 million in product sales in its first full quarter.
3Key products like Prolia® (+10%) and Repatha® (+62%) showed strong year-over-year growth.
4Net income decreased by 8% to $1.83 billion, and diluted EPS fell by 3% to $3.07, impacted by higher operating expenses.
5Operating expenses rose by 23% to $3.81 billion, largely due to Otezla-related costs and amortization of intangible assets.
6Amgen made substantial capital returns to shareholders, repurchasing $933 million in common stock and paying $945 million in dividends.
7The company is actively monitoring and responding to the COVID-19 pandemic, implementing measures to ensure business continuity and employee safety, while noting potential impacts on product demand and clinical trials.

AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2020

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions